The firm upgraded shares to outperform from market perform and raised its price target to $100 from $90. The new price target implies shares rallying 27.5%.
BMO Capital Markets says Gilead Sciences is a "best-in-class" therapy franchise that could soon see multiple expansion. "Simply put, Gilead has the best cell therapy manufacturing capabilities vs. competition from Novartis and Bristol. When comparing the three, Gilead is not supply constrained, able to meet increasing demand for Yescarta and Tecartus," BMO said in a Tuesday note.
Analyst Evan David Seigerman said that, in addition to Gilead's strong therapy franchise, its improving solid tumor oncology business and durable-growth anchored by its HIV/virology division could lead to strong growth. "Our Outperform rating is supported by our analysis of the current base business and positivity on the oncology franchise as the company's next leg of growth ," said Seigerman.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
25 Especially Child-Friendly Restaurants in San FranciscoHere’s a list of 25 of the most child-friendly restaurants in San Francisco, so everyone can have a good time when it’s time for a family meal out. (via eatersf)
Read more »
10 Things to Know About Frank Sinatra, Who Died 25 Years Ago TodayToday marks 25 years since Frank Sinatra, who remains an icon and a cultural force, died at the age of 82. Here are 10 facts you should know about him.
Read more »
New study finds lab-grown meat produces up to 25 times more CO2An interesting new study has found that lab-grown meat could be worse for the planet than traditional animal husbandry and slaughter.
Read more »
Game Of Thrones Update Means Our 25-Year-Old Dragon Dream Will Become A RealityGame of Thrones fans have had one particular dragon-related wish for a quarter of a century, and it's now much closer to finally being fulfilled.
Read more »